Parhami, Farhad
- Max Biopharma, Inc. (no department on record)
From the FY2023 NIH awards this investigator leads as contact PI. The department is the award's.
FY2023 NIH rank #11,689
- Rising Star
- Long-Funded
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID unavailableSearch this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2006 through FY2023Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.
NIH Funding · FY2023
Linked Award Amount
$897K
Full award amounts, FY2023
Award Records
1
Records listing this PI
Award-Linked Rank
#11,689
By linked amount among FY2023 PIs
Earliest Year Loaded
2006
ScienceDex PI coverage
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
FY2023 award records by amount
NIH award records listing Parhami, Farhad as a PI. Multi-PI records show the full award amount for context.
- 1R44DK136405-01R44Contact PIEvaluation of anti-fibrotic and anti-inflammatory semi-synthetic oxysterol, Oxy210, as a therapeutic drug candidate for non-alcoholic steatohepatitis$897Kaward amount
Award organization
Organizations that administered FY2023 awards listing Parhami, Farhad as a PI.
FY2023 award administered by Max Biopharma, Inc. (CA).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2006First NIH AwardMax Biopharma, Inc.
- 2007$500K Cumulative Funding
- 2009$1M Cumulative Funding
- 2013$2M Cumulative Funding
- 2022$5M Cumulative Funding
- 2022Entered Top 50% NationallyRanked #5690